Drugs in Dev. Neurology
Phase III
Ireland 
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EPIDIOLEX®/EPIDYOLEX® (cannabidiol), is a prescription, plant-derived cannabis-based medicine administered as an oral solution which contains highly purified cannabidiol (CBD).
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL
Details : If approved, XARACOLL will be Innocoll's first commercially available product in the US.
Product Name : Xaracoll
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2020
Lead Product(s) : Bupivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bupivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL
Details : Innocoll anticipates a 6-month review by the FDA.
Product Name : Xaracoll
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2020
Lead Product(s) : Bupivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
